Encompass Health (EHC) Q1 2026 Earnings Transcript

Encompass Health posted a strong Q1 with revenue up 9% to $1.59 billion and adjusted EBITDA up 11.2% to $348.8 million, prompting management to raise 2026 guidance for revenue, EBITDA, and EPS. Adjusted free cash flow was $194 million, net leverage remained low at 1.9x, and the company continued capital returns with 708,000 shares repurchased for $71.6 million plus a $0.19 quarterly dividend. Operationally, occupancy held at 78.7%, RN turnover fell to 17.8% (the lowest since at least 2012), and the company outlined ongoing expansion, AI/analytics investments, and a favorable Medicare pricing update.

Analysis

EHC is quietly transitioning from a pure occupancy story to a capacity-optimization story, which matters because it changes the earnings elasticity. The current bottleneck is not demand, but the lag between patient flow and bed supply; that tends to favor operators with faster permitting, better real estate execution, and the balance sheet to fund growth without diluting returns. The market may be underestimating how much margin can be preserved while still accelerating capex, because the business is simultaneously harvesting labor efficiency, mix, and pricing while redeploying capital into a multi-year unit rollout.

The more important second-order effect is that MA friction is becoming a revenue-quality issue rather than a simple volume headwind. If the admit-and-appeal process scales, EHC could recover a meaningful share of otherwise lost admissions, but the real upside is that it makes denials less predictive of final revenue. That would reduce the discount investors assign to MA exposure and could also pressure lower-acuity competitors that lack the operational sophistication to fight denials at scale. Conversely, if CMS tightens interpretation or appeals clog the system, the growth runway could be delayed by quarters even though end demand remains intact.

The other underappreciated angle is capital returns. With leverage still modest and FCF generation strong, buybacks are effectively a call option on execution: every incremental share retired increases EPS leverage precisely when growth capex is temporarily elevated. That creates a favorable asymmetry for equity holders over the next 12-24 months, especially if the new beds ramp faster than guided and free cash flow expands into 2027. The main risk is that management is running hard into a permitting and staffing bottleneck; if project timing slips, the market could re-rate the stock from growth compounder back to a mature healthcare yield name.

Key Decisions for Investors

• Long EHC on 6-12 month horizon: best risk/reward is that growth + buybacks + modest leverage can compound EPS faster than revenue. Use pullbacks tied to broader healthcare weakness to build.
• Pair trade: long EHC / short SEM over 3-6 months. EHC has cleaner demand visibility, better capital returns, and more actionable capacity expansion; SEM faces more execution uncertainty and less optionality from the current operating environment.
• Buy EHC Jan-2027 call spreads on weakness if shares drift on capex or regulation noise. The setup is for multiple expansion if bed additions and appeals scale without margin erosion.
• If EHC rallies sharply on guidance upgrades, trim only partially and keep a core position: the next leg depends on whether small-format hospitals and expansions convert occupancy into unit growth, which is a 2026-2027 catalyst.
• Avoid shorting CMS-sensitive post-acute names outright against EHC here; the more likely trade is a relative one, because EHC looks operationally best positioned to absorb reimbursement and utilization friction.